Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.

Cancer chemotherapy and pharmacology - 1 Jul 2012

Damodaran Solai Elango, Pradhan Suresh Chandra, Umamaheswaran Gurusamy, Kadambari Dharanipragada, Reddy K Sathyanarayana, Adithan Chandrasekaran

Abstract excerpt

PURPOSE: Tamoxifen is used in the treatment of breast cancer to prevent recurrences. It is converted to its active metabolite endoxifen by CYP2D6 enzyme. This study was conducted to evaluate the influence of CYP2D6 genetic polymorphisms on the recurrence of breast cancer in patients receiving treatment with tamoxifen as an adjuvant hormonal therapy. METHODS: Breast cancer patients (n = 141) on adjuvant tamoxifen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Kaplan-Meier Estimate

Share to Neoplasm Recurrence, Local

Share to Proportional Hazards Models

Share to Receptors, Estrogen

Share to Tamoxifen

Source

Identifiers

PMID: 22623212
DOI: 10.1007/s00280-012-1891-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.PMID 22623212Read ↗

The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.Semantic proximity Read ↗

Effect of CYP2D6 polymorphisms on breast cancer recurrence.Semantic proximity Read ↗

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.Semantic proximity Read ↗

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.Semantic proximity Read ↗

CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.Semantic proximity Read ↗

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.Semantic proximity Read ↗

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.Semantic proximity Read ↗

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.Semantic proximity Read ↗

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients.Semantic proximity Read ↗

The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.